Dynamic Technology Lab Private Ltd cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 76.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 674 shares of the company’s stock after selling 2,154 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in IDEXX Laboratories were worth $374,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Gotham Asset Management LLC boosted its holdings in IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock worth $7,620,000 after purchasing an additional 7,741 shares in the last quarter. NewEdge Wealth LLC boosted its holdings in IDEXX Laboratories by 30.4% in the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock worth $279,000 after purchasing an additional 149 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after purchasing an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. boosted its holdings in IDEXX Laboratories by 35.7% during the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after acquiring an additional 4,315 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its holdings in IDEXX Laboratories by 9.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock valued at $23,307,000 after acquiring an additional 3,627 shares during the period. 87.84% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, May 22nd. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Barclays decreased their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, Morgan Stanley decreased their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $580.38.
View Our Latest Stock Analysis on IDXX
IDEXX Laboratories Stock Up 0.1 %
NASDAQ IDXX opened at $516.50 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The firm has a 50-day simple moving average of $509.96 and a 200 day simple moving average of $524.06. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The stock has a market cap of $42.66 billion, a PE ratio of 50.00, a PEG ratio of 4.21 and a beta of 1.27.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.
Insider Buying and Selling
In related news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.11% of the company’s stock.
IDEXX Laboratories Company Profile
(Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
Receive News & Ratings for IDEXX Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEXX Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.